Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.

Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.

After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.

Claudin18.2 is out, but the US big pharma opts in to a new project.

The company sticks with EZH2, despite others adding EZH1 inhibition.

Questions continue to swirl as the unit mulls another oncology makeover.

Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.

Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.

Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.

But there are no hard facts, and a Ligand obligation clouds future licensing economics.